{"id":4647,"date":"2022-02-07T11:35:20","date_gmt":"2022-02-07T17:35:20","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=4647"},"modified":"2025-07-25T11:13:50","modified_gmt":"2025-07-25T16:13:50","slug":"nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u8996\u899a\u969c\u5bb3\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7b2c2b\u76f8\u81e8\u5e8a\u8a66\u9a13\u306e\u767b\u9332\u5b8c\u4e86\u3092\u767a\u8868"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u30c0\u30e9\u30b9\u3001, 2022 \u5e74 2 \u6708 7 \u65e5<\/span>\u00a0 \u2014\u00a0\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/a>\u7db2\u819c\u5909\u6027\u75be\u60a3\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u3092\u958b\u767a\u3059\u308b\u81e8\u5e8a\u6bb5\u968e\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u306f\u672c\u65e5\u3001\u30d5\u30a7\u30fc\u30ba\u3078\u306e\u5b8c\u5168\u767b\u9332\u3092\u767a\u8868\u3057\u305f\u3002 2b<\/span> \u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3059\u308b\u305f\u3081\u306e\u3001\u5468\u56f2\u5149\u3067\u6d3b\u6027\u5316\u53ef\u80fd\u306a\u591a\u7279\u6027\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u5149\u907a\u4f1d\u5b66\u7684\u5358\u72ec\u7642\u6cd5\u3067\u3042\u308bMCO-010\u306e\u81e8\u5e8a\u8a66\u9a13\u3002\u30c8\u30c3\u30d7\u30e9\u30a4\u30f3\u306e\u7d50\u679c\u306f\u6765\u5e74\u306e\u7b2c 1 \u56db\u534a\u671f\u306b\u4e88\u60f3\u3055\u308c\u307e\u3059\u3002<\/p>

\u201c\u300c\u3053\u306e\u6cbb\u9a13\u3078\u306e\u767b\u9332\u5b8c\u4e86\u306f\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u3068\u3001\u52b9\u679c\u7684\u306a\u6cbb\u7642\u6cd5\u306e\u306a\u3044\u7db2\u819c\u75be\u60a3\u306b\u82e6\u3057\u3080\u4f55\u767e\u4e07\u4eba\u3082\u306e\u4eba\u3005\u306b\u3068\u3063\u3066\u3001\u307e\u305f\u4e00\u3064\u91cd\u8981\u306a\u7bc0\u76ee\u3068\u306a\u308b\u300d\u3068\u8ff0\u3079\u305f\u3002 \u30b9\u30e9\u30cb\u30e3\u30fb\u30d0\u30bf\u30c1\u30e3\u30ea\u30e4<\/span>, \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306eCEO\u306f\u3001\u300c\u4eca\u56de\u306e\u6cbb\u9a13\u3067\u826f\u597d\u306a\u7d50\u679c\u304c\u5f97\u3089\u308c\u308c\u3070\u3001\u3053\u306e\u91cd\u8981\u306a\u672a\u5145\u8db3\u533b\u7642\u30cb\u30fc\u30ba\u306e\u5b9f\u73fe\u306b\u4e00\u6b69\u8fd1\u3065\u304f\u3053\u3068\u306b\u306a\u308b\u3067\u3057\u3087\u3046\u300d\u3068\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u201c<\/p>

MCO-010\u306e\u30d5\u30a7\u30fc\u30ba1\/2a\u8a66\u9a13\u3092\u5b8c\u4e86<\/a>\u00a011\u4eba\u306eRP\u60a3\u8005\u3067\u306f\u3001\u5149\u907a\u4f1d\u5b66\u7642\u6cd5\u306e\u5fcd\u5bb9\u6027\u304c\u826f\u597d\u3067\u3001\u9032\u884c\u3057\u305fRP\u60a3\u8005\u306b\u304a\u3051\u308b\u6a5f\u80fd\u7684\u8996\u899a\u306e\u5927\u5e45\u306a\u6539\u5584\u3068\u4e00\u81f4\u3057\u3066\u751f\u6d3b\u306e\u8cea\u304c\u6539\u5584\u3055\u308c\u305f\u3053\u3068\u304c\u5b9f\u8a3c\u3055\u308c\u307e\u3057\u305f\u3002<\/p>

\u30d5\u30a7\u30fc\u30ba 2b<\/span> \u30c8\u30e9\u30a4\u30a2\u30eb \uff08NCT04945772<\/a><\/u>\uff09\u306f\u3001\u7121\u4f5c\u70ba\u5316\u3001\u4e8c\u91cd\u30de\u30b9\u30af\u3001\u507d\u5bfe\u7167\u3001\u591a\u65bd\u8a2d\u5171\u540c\u8a66\u9a13\u306b\u3001\u9032\u884c\u6027RP\u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u60a3\u304627\u4eba\u306e\u53c2\u52a0\u8005\u3092\u767b\u9332\u3057\u305f\u3002\u3053\u306e\u7814\u7a76\u3067\u306f\u3001\u60a3\u8005\u306f MCO-010 \u306e\u6ce8\u5c04\u307e\u305f\u306f\u507d\u6ce8\u5c04\u3092\u53d7\u3051\u3066\u3001MCO-010 \u7642\u6cd5\u306e\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u3092\u8a55\u4fa1\u3057\u307e\u3059\u3002<\/p>

\u201c\u300c\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306f\u3001\u3055\u307e\u3056\u307e\u306a\u907a\u4f1d\u5b50\u5909\u7570\u306b\u3088\u3063\u3066\u5f15\u304d\u8d77\u3053\u3055\u308c\u308b\u9032\u884c\u6027\u306e\u907a\u4f1d\u6027\u75be\u60a3\u3067\u3059\u3002\u3053\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u306f\u3001\u3055\u307e\u3056\u307e\u306a\u907a\u4f1d\u5b50\u578b\u306eRP\u60a3\u8005\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u300d\u3068\u8ff0\u3079\u305f\u3002 \u30d0\u30a4\u30ed\u30f3\u30fb\u30e9\u30e0<\/span>\u3001\u533b\u5b66\u535a\u58eb\u3001\u30d0\u30b9\u30b3\u30e0\u30fb\u30d1\u30fc\u30de\u30fc\u773c\u79d1\u7814\u7a76\u6240\u306e\u795e\u7d4c\u773c\u79d1\u6559\u6388\u3001RP\u306e\u7b2c\u4e00\u4eba\u8005\u3002<\/p>

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306e\u5149\u907a\u4f1d\u5b66\u7642\u6cd5\u306f\u72ec\u81ea\u306e\u6280\u8853\u3092\u4f7f\u7528\u3057\u3066\u3044\u307e\u3059 AAV2<\/i> MCO \u907a\u4f1d\u5b50\u3092\u7db2\u819c\u7d30\u80de\u306b\u5c0e\u5165\u3057\u3001\u81ea\u7136\u74b0\u5883\u3067\u306e\u8996\u899a\u3092\u53ef\u80fd\u306b\u3059\u308b\u30d9\u30af\u30bf\u30fc\u3002\u3053\u306e\u7642\u6cd5\u306f\u3001\u4ed6\u306e\u88c5\u7f6e\u3084\u4ecb\u5165\u3092\u5fc5\u8981\u3068\u305b\u305a\u3001\u30aa\u30d5\u30a3\u30b9\u5185\u3067\u5358\u773c\u6ce8\u5c04\u3068\u3057\u3066\u6295\u4e0e\u3055\u308c\u307e\u3059\u3002\u7b2c 1\/2a \u76f8\u8a66\u9a13\u306e\u8a3c\u62e0\u306b\u57fa\u3065\u304f\u3068\u3001MCO-010 \u306f\u907a\u4f1d\u5b50\u5909\u7570\u306b\u95a2\u4fc2\u306a\u304f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u304a\u3051\u308b\u8996\u529b\u56de\u5fa9\u306b\u5fdc\u7528\u3067\u304d\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002 MCO-010 \u306f\u3001FDA \u304b\u3089 RP \u304a\u3088\u3073\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u75c5\u306b\u5bfe\u3059\u308b\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u306e\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u9ec4\u6591\u5909\u6027\u75c7\u306e\u7b2c 2 \u76f8\u7814\u7a76\u3082\u958b\u59cb\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>

RP\u306b\u3064\u3044\u3066\u00a0
<\/b>RP \u306f 100 \u3092\u8d85\u3048\u308b\u7570\u306a\u308b\u907a\u4f1d\u5b50\u5909\u7570\u306b\u95a2\u9023\u3057\u3066\u304a\u308a\u3001\u5149\u53d7\u5bb9\u4f53\u304c\u52a3\u5316\u3057\u3066\u7d04 200 \u4e07\u4eba\u304c\u5931\u660e\u306b\u81f3\u308b\u4e00\u9023\u306e\u7a00\u306a\u75be\u60a3\u3092\u542b\u3093\u3067\u3044\u307e\u3059\u3002<\/p>

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306b\u3064\u3044\u3066
<\/b>Nanoscope Therapeutics \u306f\u3001\u6cbb\u7642\u6cd5\u304c\u5b58\u5728\u3057\u306a\u3044\u7db2\u819c\u75be\u60a3\u306b\u82e6\u3057\u3080\u4f55\u767e\u4e07\u3082\u306e\u8996\u899a\u969c\u5bb3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3059\u308b\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u30d1\u30a4\u30d7\u30e9\u30a4\u30f3\u306b\u306f\u3001RP\u3001\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u3001\u4e7e\u6027AMD\u306b\u5bfe\u3059\u308b\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u304c\u542b\u307e\u308c\u3066\u3044\u307e\u3059\u3002<\/p>

\u63a5\u89e6\uff1a
<\/b>\u30c0\u30f3\u30fb\u30a8\u30e9\u30df\u30a2\u30f3<\/span>
\u30aa\u30fc\u30d1\u30b9\u30fb\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u30fb\u30b3\u30df\u30e5\u30cb\u30b1\u30fc\u30b7\u30e7\u30f3\u30ba
pr@nanostherapeutics.com<\/a>
425-306-8716<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS, Feb. 7, 2022\u00a0 \u2014\u00a0Nanoscope Therapeutics, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2b clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in patients with retinitis pigmentosa (RP). Topline results are expected in Q1 of next year. \u201cCompleting enrollment for this trial is another important milestone for Nanoscope and millions suffering from retinal diseases for which there are no effective treatments,\u201d said Sulagna Bhattacharya, CEO of Nanoscope. \u201cPositive results from this trial will bring us closer to meeting this significant unmet medical need.\u201d A Completed Phase 1\/2a study of MCO-010\u00a0in 11 patients […]<\/p>\n","protected":false},"author":6,"featured_media":4650,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-4647","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-07T17:35:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-25T16:13:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision\",\"datePublished\":\"2022-02-07T17:35:20+00:00\",\"dateModified\":\"2025-07-25T16:13:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/\"},\"wordCount\":405,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/NSCOPE_LI_fullenrollment.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/\",\"name\":\"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/NSCOPE_LI_fullenrollment.jpg\",\"datePublished\":\"2022-02-07T17:35:20+00:00\",\"dateModified\":\"2025-07-25T16:13:50+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/NSCOPE_LI_fullenrollment.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/NSCOPE_LI_fullenrollment.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/02\\\/07\\\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u5931\u660e\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u907a\u4f1d\u5b50\u6cbb\u7642\u306b\u95a2\u3059\u308b\u7b2c2b\u76f8\u81e8\u5e8a\u8a66\u9a13\u306e\u88ab\u9a13\u8005\u767b\u9332\u5b8c\u4e86\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2022-02-07T17:35:20+00:00","article_modified_time":"2025-07-25T16:13:50+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision","datePublished":"2022-02-07T17:35:20+00:00","dateModified":"2025-07-25T16:13:50+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/"},"wordCount":405,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/","url":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u5931\u660e\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u907a\u4f1d\u5b50\u6cbb\u7642\u306b\u95a2\u3059\u308b\u7b2c2b\u76f8\u81e8\u5e8a\u8a66\u9a13\u306e\u88ab\u9a13\u8005\u767b\u9332\u5b8c\u4e86\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg","datePublished":"2022-02-07T17:35:20+00:00","dateModified":"2025-07-25T16:13:50+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/02\/NSCOPE_LI_fullenrollment.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2022\/02\/07\/nanoscope-therapeutics-announces-completed-enrollment-of-its-phase-2b-clinical-trial-in-blind-patients-for-optogenetic-gene-therapy-to-restore-vision\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/4647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=4647"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/4647\/revisions"}],"predecessor-version":[{"id":9240,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/4647\/revisions\/9240"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/4650"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=4647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=4647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=4647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}